| Project/Area Number |
16K21329
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Metabolomics
Orthopaedic surgery
|
|---|
| Research Institution | Saitama Medical University |
|---|
Principal Investigator |
|
|---|
| Research Collaborator |
MIMUA Toshihide 埼玉医科大学, 医学部, 教授
AIZAKI Yoshimi 埼玉医科大学, 医学部, 助手
|
|---|
| Project Period (FY) |
2016-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2017: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2016: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
|
|---|
| Keywords | 自己免疫性疾患 / 関節リウマチ / 全身性骨代謝異常 / 骨粗鬆症 / 破骨細胞 / 破骨細胞様細胞 / 炎症性サイトカイン / 抗環状シトルリン化ペプチド抗体 / 抗CCP抗体 / 骨代謝異常 / 免疫学 |
|---|
| Outline of Final Research Achievements |
It is well known that systemic autoimmune disease potentiates osteoporosis but the underlying mechanism is not known. In the current study, we revealed that differentiation potential of bone-resorbing cells, i.e., osteoclasts and osteoclast-like cells derived from the peripheral blood of patients with rheumatoid arthritis (RA), was significantly higher than that of healthy volunteers (both, n=6). In addition, we confirmed that the differentiation potential of bone-resorbing cells was most closely associated with the titer of the anti-cyclic citrullinated peptide antibody (ACPA). Furthermore, in RA patients with high ACPA titer (n=4, more than 40 U/mL), systemic bone mineral density was significantly lower than in RA patients with low ACPA titer (n=4, less than 40 U/mL）. From the above, ACPA titer might be a new predictive factor of osteoporosis in patients with systemic autoimmune disease, such as RA.
|
